Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Centre F. Baclesse, Caen, France

Survival: 25.7 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Gemzar
Country: France
City/State/Province: Caen
Hospital: Centre F. Baclesse
Journal: Link
Date: 11/2005

Patients: This Phase II study involved 40 women with metastatic breast cancer. The median age was 61.5 years. Metastatic sites included viscera, lung, and liver. None of the patients had received primary chemotherapy treatment before the study.

Treatment: The treatment consisted of two chemotherapeutic agents: gemcitabine and paclitaxel.

Toxicity: Grade 3-4 toxicities included neutropenia, thrombocytopenia, leukopenia, anemia, and alopecia.

Results: The median overall survival was 25.7 months. Two patients had complete responses, twelve had partial responses, and fourteen achieved stable disease.

Support: Eli Lilly and Company helped the investigators with study design, analysis and interpretation of data; writing of the manuscript, and in the decision to submit the manuscript for publication. Furthermore, several authors are or were employees of Eli Lilly. Eli Lilly manufactures and/or markets gemcitabine.

Correspondence: Jean-Yves Genot, MD

E-mail to a Friend Email Physician More Information